Novo Nordisk readies trial results for next-generation weight-loss drug Date Saturday, November 16, 2024 - 10:01 PM Description Danish company expects data to show that CagriSema cuts weight by 25 per cent in just over a year
Novo Nordisk seeks to use obesity drug findings to prevent weight gain Date Monday, December 04, 2023 - 10:00 PM Description Pharma group behind blockbuster drug wants to supersize its market impact
Novo Nordisk shares fall on latest trial results for new obesity drug Date Monday, March 10, 2025 - 9:56 AM Description Participants with type 2 diabetes had an average weight loss of 15.7 per cent after 68 weeks on CagriSema
Novo Nordisk shares jump up on latest weight loss trial results Date Friday, January 24, 2025 - 10:21 AM Description People treated with amycretin lost up to 22% of their body weight after 36 weeks
Novo Nordisk shares tumble as data on weight-loss drug trial disappoints Date Friday, December 20, 2024 - 10:39 AM Description Obesity treatment CagriSema misses goal of 25% reduction in body weight
Novo Nordisk signs deals worth up to $1bn with US biotechs in race for obesity drugs Date Thursday, January 04, 2024 - 8:44 AM Description Danish manufacturer Wegovy invests in two start-ups as part of efforts to stay ahead in major new market
Novo Nordisk warns EU that new rules will push it to expand faster in US Date Sunday, November 05, 2023 - 4:01 PM Description Drugmakers claim that Brussels’ market exclusivity overhaul will reduce R&D investment
Novo Nordisk ‘surprised’ by high European demand for weight-loss drugs Image Date Saturday, February 03, 2024 - 10:00 PM Description Chief executive says customers very willing to pay for Wegovy from their own pockets
Novo Nordisk’s drug stumble leaves it suddenly much slimmer Date Friday, December 20, 2024 - 8:15 AM Description Market will never be winner takes all given that different patients will have different requirements
Novo Nordisk’s obesity drug cuts risk of death by 18%, trial data shows Date Saturday, November 11, 2023 - 6:30 AM Description Wegovy found to have ‘quite profound’ effect on reducing risk of heart attacks, says pharma group